Biologics such as dupilumab and tralokinumab primarily target type 2 inflammation by inhibiting IL-4, IL-13, or IL-13 alone, making them effective for patients whose AD is predominantly driven by the TH2 pathway [17,25]. The gene discussed is IL4; the disease is Alzheimer disease.